Show simple item record

dc.contributor.authorDavies, A
dc.contributor.authorTrask, P
dc.contributor.authorDemeter, J
dc.contributor.authorFlorschuetz, A
dc.contributor.authorHaenel, M
dc.contributor.authorKinoshita, T
dc.contributor.authorPettengell, R
dc.contributor.authorQuach, H
dc.contributor.authorRobinson, S
dc.contributor.authorSadullah, S
dc.contributor.authorSancho, J-M
dc.contributor.authorUdvardy, M
dc.contributor.authorWitzens-Harig, M
dc.contributor.authorKnapp, A
dc.contributor.authorLiu, W
dc.date.accessioned2020-11-26T22:55:43Z
dc.date.available2020-11-26T22:55:43Z
dc.date.issued2020-04-20
dc.identifierpii: 10.1007/s00277-020-04021-6
dc.identifier.citationDavies, A., Trask, P., Demeter, J., Florschuetz, A., Haenel, M., Kinoshita, T., Pettengell, R., Quach, H., Robinson, S., Sadullah, S., Sancho, J. -M., Udvardy, M., Witzens-Harig, M., Knapp, A. & Liu, W. (2020). Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma. ANNALS OF HEMATOLOGY, 99 (12), pp.2837-2846. https://doi.org/10.1007/s00277-020-04021-6.
dc.identifier.issn0939-5555
dc.identifier.urihttp://hdl.handle.net/11343/252044
dc.description.abstractHealth-related quality of life was a secondary endpoint in the phase III GALLIUM study in previously untreated patients with follicular lymphoma who were treated with rituximab- or obinutuzumab-chemotherapy. Patients were randomized 1:1 to receive induction therapy with obinutuzumab- or rituximab-chemotherapy and maintenance in responders. Health-related quality of life was assessed using the Functional Assessment of Cancer Treatment-Lymphoma questionnaire, incorporating well-being and lymphoma-specific subscales. Assessments were performed at baseline, and during induction, maintenance, and follow-up (maximum 84 months). Clinically meaningful responses were defined by minimally important difference values. Of 1202 randomized patients (median follow-up 57.4 months), 557/601 (92.7%; obinutuzumab-chemotherapy) and 548/601 (91.2%; rituximab-chemotherapy) completed all Functional Assessment of Cancer Treatment-Lymphoma scales at baseline. Mean baseline health-related quality of life scores were similar between both arms, with all patients having some functional impairment and lymphoma symptoms. Over the course of treatment, mean health-related quality of life remained similar in both arms. Equal proportions of patients in both arms achieved minimally important difference by the Functional Assessment of Cancer Treatment-Lymphoma lymphoma-specific subscale and summary scales throughout induction, maintenance, and follow-up. On each summary scale, ~ 50% of patients in each arm achieved minimally important difference by maintenance month 2. In GALLIUM, similar improvements in health-related quality of life were seen with obinutuzumab- and rituximab-chemotherapy, suggesting that both treatments reduced lymphoma-related symptoms, and treatment-related side effects did not abrogate these improvements in well-being. ClinicalTrials.gov identifier: NCT01332968.
dc.languageEnglish
dc.publisherSPRINGER
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleHealth-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma
dc.typeJournal Article
dc.identifier.doi10.1007/s00277-020-04021-6
melbourne.affiliation.departmentMedicine (St Vincent's)
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titleAnnals of Hematology
melbourne.source.volume99
melbourne.source.issue12
melbourne.source.pages2837-2846
dc.rights.licenseCC BY
melbourne.elementsid1446424
melbourne.contributor.authorQuach, Hang
dc.identifier.eissn1432-0584
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record